Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Investigational Cancer Drug · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Investigational Cancer Drug | DRUG | - |
Inclusion Criteria: (The patient must meet the following criteria in order to be eligible for this study.) * Signed informed consent * No more than two prior regimens for metastatic breast cancer. Each regimen must have contained Herceptin. * Refractory Stage IIIb or IV breast cancer * HER2/neu tum...
Top 20 of 92 competitors
Investigational Cancer Drug is a small molecule being studied for the treatment of metastatic breast cancer. It was evaluated in a Phase 2 clinical trial in women with refractory metastatic breast cancer who had received prior first-line or second-line Herceptin therapy. The drug remains investigational and is not approved.
Investigational Cancer Drug is being developed by GSK plc, which trades under the ticker GSK. The company sponsored a Phase 2 clinical trial of the drug in metastatic breast cancer. GSK is the developer of this investigational oncology asset.
Investigational Cancer Drug is in Phase 2 clinical development. It has completed one Phase 2 trial in metastatic breast cancer. The drug is investigational and has not been approved by regulatory authorities. Its development status is based on the completed Phase 2 study.
Investigational Cancer Drug has one completed clinical trial, NCT00051103, a Phase 2 study in women with refractory metastatic breast cancer after first-line or second-line Herceptin. The trial was conducted in the United States and enrolled female patients aged 18 years and older. It was an uncontrolled, non-randomized study.
Investigational Cancer Drug is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial in metastatic breast cancer. The drug is still in clinical development and has not received marketing approval from the FDA or other regulatory agencies.